Blue light cystoscopy is guidelines recommended to improve bladder cancer detection and decrease recurrence. Now, ForTec offers a mobile solution to bring the technology to you without a costly capital investment!
The Challenge of Bladder Cancer Diagnosis
Bladder cancer impacts over 700,000 patients in the US—each year more than 80,000 people will be diagnosed. Sometimes, bladder tumors can blend in with normal healthy tissue, leading to missed diagnosis or incomplete removal, which in turn can lead to cancer recurrence.
Making Cancer Visible
The Karl Storz Blue Light Cystoscopy used with a pharmaceutical imaging agent is the first FDA approved technology for enhanced detection of bladder cancer. The imaging agent makes abnormal cells glow bright pink under blue light, allowing for more complete tumor resection.
Guideline-Recommended Care
The 2016 AUA/SUO guideline states in a patient with non-muscle invasive bladder cancer, a clinician should offer Blue Light Cystoscopy if available to increase detection and decrease recurrence.
ForTec’s Mobile Solution: Innovation Without the Overhead
The ForTec mobile technology service makes Blue Light Cystoscopy available without a costly capital investment up front. Knowledgeable technologists support the equipment, with no worries about maintenance or broken devices.
The Bottom Line
Patients and surgeons want state-of-the-art technology to obtain the most optimal cancer outcomes—Blue Light Cystoscopy has been shown to improve cancer detection and decrease recurrence. Now, this technology is available in a mobile solution—without a costly up-front capital investment!
